<DOC>
	<DOCNO>NCT02588794</DOCNO>
	<brief_summary>Aim study reduce incidence RIFLE stadium L E acute kidney injury patient severe sepsis/septic shock</brief_summary>
	<brief_title>Cytokine Adsorption Sepsis Acute Kidney Injury</brief_title>
	<detailed_description>Patient prove severe sepsis/septic shock , treat accordance actual sepsis guideline , develope akute kidney injury ( RIFLE I ) kidney failure ( RIFLE F ) , randomize two group . One group treat CVVHD/ local citrat anticoagulation ( standart clinical practice ) . The group ist treat additional cytokine adsorber ( 300ml CytoSorb device , 3804606CE01 ) CytoSorb therapy perform 24h , adsorber change new device . Cytosorb therapy stop , Interleukin 6 leves drop 1000 pg/ml patient serum .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>severe sepsis septic shock accord ESICM guideline older 24 h preexist renal disease KDIGO stadium 4 5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>sepsis , acute kidney injury , CytoSorb</keyword>
</DOC>